Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
Adia MED of Winter Park LLC Autisme Spektrum Forstyrrelse Forskningsstudie
This 12-month study tests whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3-12. About 100 children with confirmed autism will be randomly assigned to one of two groups. One group receives monthly IV AdiaVita plus IV glutathione for 3 months. The other group receives IV glutathione plus a saline placebo infusion for 2 months. Both groups also use a topical glutathione spray twice a day at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC), completed by a parent and by a therapist or teacher. Safety is monitored at clinic visits through Month 12. Children who first receive glutathione only, may crossover to receive AdiaVita at no extra cost if they stay medically stable and their family agrees. Participation is voluntary. The study fee is $12,000.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Larry Powalisz
- Telefonnummer: 3217880850
- E-post: research@adiamed.com
Studiesteder
-
-
Florida
-
Winter Park, Florida, Forente stater, 32789
- Rekruttering
- Adia Med Of Winter Park
-
Ta kontakt med:
- Dr Thomas MD, MD
- Telefonnummer: 3212312843
- E-post: research@adiamed.com
-
-
Wisconsin
-
Green Bay, Wisconsin, Forente stater, 54311
- Rekruttering
- The Lyday Center
-
Ta kontakt med:
- Rhonda Hilgenberg
- Telefonnummer: 9203843110
- E-post: rhondah@thelydaycenter.com
-
Ta kontakt med:
- Alina P
- Telefonnummer: 9203013619
- E-post: alinap@thelydaycenter.com
-
Hovedetterforsker:
- Tami Lyday, DO
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age 3-12 years
- Confirmed ASD diagnosis (DSM-5 criteria, supported by ADOS-2)
- Parent/guardian willingness to consider experimental treatments and comply with study requirements
- Ability to attend all scheduled visits
- Able to meet study cost requirements ($12,000 study fee plus bloodwork costs, if applicable) as described in the informed consent
Exclusion Criteria:
- Severe allergies to study products
- Significant uncontrolled medical conditions
- Pregnancy or breastfeeding (if applicable)
- Participation in another interventional trial within 30 days
- Prior stem cell or glutathione therapy: History of stem cell therapy (including umbilical cord blood-derived stem cells or exosomes) or glutathione therapy (intravenous or topical) at any time prior to screening
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Glutathion med stamceller
|
Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes. Reduced L-glutathione administered Intravenous infusion. |
|
Aktiv komparator: Glutation Alene
|
Reduced L-glutathione administered Intravenous infusion. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 6
Tidsramme: Baseline and Month 6
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 6
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events
Tidsramme: Baseline through Month 12
|
Baseline through Month 12
|
|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 3
Tidsramme: Baseline and Month 3
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 3
|
|
Change from Baseline in Total Autism Treatment Evaluation Checklist (ATEC) Score at Month 12
Tidsramme: Baseline and Month 12
|
The Autism Treatment Evaluation Checklist (ATEC) is a caregiver-completed questionnaire designed to evaluate treatment effectiveness in autism by assessing symptoms across four domains (Speech/Language/Communication, Sociability, Sensory/Cognitive Awareness, and Health/Physical/Behavior). Total ATEC scores range from 0 to 180, with higher scores indicating greater severity of autism symptoms (worse outcome) and lower scores indicating fewer symptoms (better outcome). |
Baseline and Month 12
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
- Oksidativt stress
- ASD
- Autisme
- Autismespektrumforstyrrelse
- Mesenkymale stamceller
- Glutation
- Regenerativ medisin
- Cellulær terapi
- MSC-er
- Immunmodulasjon
- Stamcelleterapi
- Antioksidantterapi
- Allogene stamceller
- Anti-inflammatorisk terapi
- Intravenøs glutathion
- Glutationterapi
- Autismesymptomer
- Hematopoietiske stamceller (HSCs)
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- Adia Med ASD Research Study
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .